---
title: Crystec Limited (CrystecPharma) vs Flamma
slug_a: crystecpharma
slug_b: flammagroup
site: cdmo
review_signal_gate: closed
canonical_path: /compare/crystecpharma/flammagroup
---

# Crystec Limited (CrystecPharma) vs Flamma

Side-by-side profile data from each company listing on this directory.

## Crystec Limited (CrystecPharma)

- Profile: [/companies/crystecpharma](/companies/crystecpharma)

Crystec Limited (CrystecPharma) — Crystec Limited (CrystecPharma) is a pharmaceutical technology company that offers its mSAS® supercritical-fluid particle engineering platform to improve the bioavailability, stability and delivery of small and large molecule therapeutics. Its work is aimed at clients developing new and existing medicines.

Services: 4. Modalities: 5. Indications: 1. Locations: 4. Certifications: 0. The strongest documented coverage currently appears in modalities (5).

### Services

- Solid-State Chemistry & Polymorph Screening
- Inhalation & Nasal Dosage Manufacturing
- Process Development
- Formulation Development

### Modalities

- Small Molecule
- Biologics (Monoclonal Antibodies)
- Biologics (Other)
- Oligonucleotide
- Peptide

### Development capabilities

- Formulation development

### Manufacturing capabilities

- Data not yet provided.

## Flamma

- Profile: [/companies/flammagroup](/companies/flammagroup)

Flamma — Privately held small molecule CDMO with FDA-inspected cGMP facilities in Italy, USA, and China, offering custom manufacturing, development, and specialized technologies including HPAPI, continuous flow, and cryogenic API synthesis from early-stage to commercial scale.

Services: 9. Modalities: 1. Indications: 0. Locations: 7. Certifications: 1. The strongest documented coverage currently appears in services (9).

### Services

- API Synthesis & Manufacturing
- HPAPI Manufacturing (High-Potency)
- Flow Chemistry & Continuous Manufacturing
- Solid-State Chemistry & Polymorph Screening
- Process Development
- Formulation Development
- Technology Transfer
- CMC Analytical Development
- CMC Regulatory Submission Support

### Modalities

- Small Molecule

### Development capabilities

- Analytical method development
- Formulation development
- Solid-state characterization

### Manufacturing capabilities

- Drug Substance (DS)
- HPAPI
- Flow Chemistry
- Cryogenic (−80 °C)